OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis

Company Overview

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.89 to $0.89
• 52-Week Range: N/A
• Volume: 1,201 shs
• Average Volume: 768,904 shs
• Market Capitalization: $34.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OMED Stock Analysis - Frequently Asked Questions

How were OncoMed Pharmaceuticals' earnings last quarter?

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. OncoMed Pharmaceuticals had a negative trailing twelve-month return on equity of 13.14% and a negative net margin of 18.24%.

What other stocks do shareholders of OncoMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS).

Company Calendar

• Last Earnings: 11/01/2018
• Today: 8/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OMED
• CIK: 1302573
• Web: www.oncomed.com
• Phone: 650-995-8200
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.10 million
• Net Margins: -18.24%
• Pretax Margin: N/A
• Return on Equity: -13.14%
• Return on Assets: -7.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: $44.42 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 38,690,000
• Free Float: N/A
• Market Cap: $34.43 million
• Optionable: Optionable
• Beta: 1.86